Imdur (Isosorbide Mononitrate)

After oral absorption, isosorbide mononitrate is converted to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of arteries and veins, lowering cardiac preload and afterload, and ultimately decreasing the heart’s oxygen demand during exertion.

The appropriate dose of Imdur is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any concurrent medications. Dosage adjustments may be required for special populations, and patients should follow the specific instructions provided by their healthcare professional.

Imdur is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should only be used during pregnancy or lactation when clearly needed and after a risk‑benefit assessment by the prescriber.

To request Imdur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imdur belongs to the nitrate class, offering long‑acting vasodilation, whereas other anti‑anginals such as beta‑blockers reduce heart rate and calcium‑channel blockers relax vascular smooth muscle via different pathways. Nitrates are particularly effective for patients who need prophylactic relief of angina, but tolerance can develop, so clinicians may rotate or combine therapies based on individual response.

Imdur tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Imdur is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush, chew, or split the tablet unless specifically instructed, as this could affect the drug’s release profile.

The most serious adverse events include severe hypotension, which can lead to syncope, and rare allergic reactions such as rash, swelling, or difficulty breathing. Patients should seek immediate medical attention if they experience sudden fainting, chest pain that does not improve, or signs of a severe allergic response.

Imdur should be avoided in patients with known hypersensitivity to isosorbide mononitrate or any other nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24 hours, and individuals with severe anemia, closed‑angle glaucoma, or uncontrolled hypotension. Clinicians must assess each patient’s medical history before initiating therapy.